REVEALED: Medtronics q2 2027 earnings what to expect | Vintage Vibes

Galway, Ireland-based Medtronic plc (MDT) develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients. Valued at $121.2 billion by market cap, the company's principal products include those for bradycardia pacing, tachyarrhythmia management, atrial fibrillation management, heart failure management, heart valve replacement, malignant and non-malignant pain, and movement disorders. The medical devices giant is expected to announce its fiscal second-quarter earnings for 2027 in the near term.

Ahead of the event, analysts expect Medtronic to report a profit of $1.34 per share on a diluted basis, down 1.5% from $1.36 per share in the year-ago quarter. The company has consistently surpassed Wall Street’s EPS estimates in its last four quarterly reports.